-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
UK NHS cost regulators have provided financial support for the Alexion's Ondexxya (andexanet alfa), to reverse the direct factor Xa (FXa) inhibitor apixaban ( apixaban ) or rivaroxaban (rivaroxaban) anticoagulation, Argentina Pixaban or rivaroxaban may cause fatal or uncontrolled bleeding from the gastrointestinal (GI) of the patient.
Apixaban
To date, there is no licensed therapy to reverse the major bleeding associated with apixaban or rivaroxaban.
Prevent thrombosis
FXa inhibitors can normally prevent blood clotting to prevent the formation of unnecessary blood clots, but doing so can also increase the risk of serious and potentially life-threatening bleeding.
Studies have shown that Ondexxya can reverse the anticoagulant effects of apixaban or rivaroxaban within two minutes after administration.
Studies have shown that Ondexxya can reverse the anticoagulant effects of apixaban or rivaroxaban within two minutes after administration.
medsci.
Original source:
Original source:href="" target="_blank" rel="noopener">Leave a message here